Seaport Therapeutics Secures $225 Million Financing Round
BOSTON -- Seaport Therapeutics, a clinical-stage biopharmaceutical company, has announced the successful closing of an oversubscribed $225 million Series B financing round. This substantial funding will support the company in advancing its innovative neuropsychiatric medicines.
Investors Backing Seaport Therapeutics
The financing efforts were spearheaded by General Atlantic, a prominent global growth investor. Notable participants include funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and additional new investors. Original backers such as ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and co-founder PureTech Health also contributed to this round.
Significance of the Funding
This recent funding effort raises the total capital raised by Seaport to an impressive $325 million since its inception. The funds will primarily be utilized to propel the Company’s clinical-stage pipeline of medications toward significant milestones, as well as to expand the capabilities of the Glyph™ technology platform that has already shown clinical proof-of-concept.
Daphne Zohar's Vision for Mental Health
“We are deeply thankful for the opportunity to partner with this exceptional group of investors,” stated Daphne Zohar, Founder and CEO of Seaport Therapeutics. “Together, we aim to deliver superior medicines for individuals struggling with mental health conditions such as depression and anxiety. Our mission continues as we advance innovative therapeutics that deliver clinically proven outcomes, overcoming barriers that have previously restricted their development.”
Expert Insights into Seaport's Potential
Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, expressed enthusiasm about the partnership. “We are extremely impressed with Seaport’s impressive CNS clinical track record and exceptional team. The setup for clinical development, combined with the innovative nature of the Glyph platform, signals a promising direction for the Company’s future,” noted Zbar.
Understanding the Glyph™ Technology Platform
The Glyph technology platform is a proprietary system that enhances drug absorption via the lymphatic system, enabling a more efficient route for oral drug delivery. This advancement minimizes first-pass metabolism and mitigates potential liver-related side effects that typically hinder many therapeutic candidates.
Seaport's Advanced Therapeutic Candidates
Among the leading candidates in the pipeline is SPT-300, an oral prodrug of allopregnanolone currently moving into a Phase 2b trial targeting major depressive disorder accompanied by or without anxious distress. Allopregnanolone is recognized for its rapid antidepressant and anxiolytic effects, and SPT-300 retains these benefits in an orally administered format.
SPT-320, another promising candidate, serves as a novel agomelatine prodrug entering Phase 1 trials for generalized anxiety disorder (GAD). This innovative approach leverages the Glyph platform to bypass the liver’s initial breakdown, potentially allowing lower dosages that reduce liver exposure while maintaining efficacy.
In addition to SPT-300 and SPT-320, Seaport is also developing SPT-348, distinguished by its non-hallucinogenic neuroplastogen properties, aimed at treating various mood and neuropsychiatric disorders. Multiple discovery and preclinical projects are also in progress to further enrich Seaport’s therapeutic landscape.
About Seaport Therapeutics
Seaport Therapeutics is dedicated to developing revolutionary neuropsychiatric medicines addressing critical gaps in patient care. With a robust strategy grounded in advanced mechanisms and the proprietary Glyph platform, the company is well-positioned to tackle medication challenges relating to bioavailability and side effects. Led by a highly experienced team and supported by a broad network of scientists and clinicians, Seaport is making strides toward better mental health solutions.
Frequently Asked Questions
What is the significance of Seaport's recent financing round?
The recent $225 million financing is crucial for advancing their neuropsychiatric medicine pipeline and expanding the capabilities of their unique Glyph technology.
Which investors participated in this financing round?
Notable investors include General Atlantic, T. Rowe Price Associates, and Goldman Sachs Alternatives, among others.
How does the Glyph platform benefit drug development?
The Glyph platform enhances oral drug availability and eliminates first-pass metabolism, thereby reducing side effects for better therapeutic outcomes.
What are some therapeutic candidates being developed by Seaport?
Seaport is advancing several candidates, including SPT-300 for major depressive disorder and SPT-320 for generalized anxiety disorder.
What is Seaport Therapeutics' mission?
The mission of Seaport Therapeutics is to advance effective neuropsychiatric medicines to meet the substantial unmet needs of patients suffering from mental health disorders.
